ISCHEMIC STROKE
Stroke-related epilepsy (STRE)
Updated on 21/05/2024, published on 22/12/2023
- stroke, both ischemic and hemorrhagic, is a significant cause of seizures, especially in the elderly patients
- stroke accounts for ~ 50% of newly diagnosed seizures among the elderly
- stroke patients have about an 11.5% risk of single or recurrent seizures in the first 5 years after a stroke (Burn, 1997)
- the incidence and prevalence of post‐stroke seizures and post‐stroke epilepsy are likely to rise in the future
- seizures may occur as a consequence of any type of stroke (ischemic stroke, intracerebral and subarachnoid hemorrhage, and cerebral sinus thrombosis with venous infarction)
- stroke-related (post‐stroke) seizures and stroke-related (post‐stroke) epilepsy (STRE) are common causes of hospital admissions
- they generally have a favorable prognosis and can be effectively managed using antiseizure medication (ASM)
- < 25% of cases become drug-resistant
- seizures may result in increased morbidity, longer hospital stays, significant disability after discharge, and higher resource utilization
- they generally have a favorable prognosis and can be effectively managed using antiseizure medication (ASM)
- controlled trials are needed to explore the primary and secondary prevention of STRE and to provide high-quality evidence on the efficacy and tolerability of ASM to guide treatment
Classification
The classification of post‐stroke seizure (stroke-related seizure) and post‐stroke epilepsy (stroke-related epilepsy) follows a two-step process:
- classification of seizures according to standardized diagnostic (revised) guidelines of the International League Against Epilepsy (ILAE)
- determination of the relation of the seizures to the cerebrovascular event
- stroke-related seizures – isolated or infrequent seizures that occur as a direct result of a stroke and may be early or late-onset
- early-onset seizures (within 7-14 days of stroke onset, with a peak within 24 hours)
- the time frame varies in different clinical definitions and reports; generally, they occur soon after stroke onset
- early-onset seizures belong to acute symptomatic seizure (ASS)
- early seizures are believed to be the consequence of local metabolic disturbances
- late-onset seizures (> 7-14 days after stroke onset)
- late seizures are thought to occur when the brain has acquired a predisposition to seizures
- late-onset seizures have a higher recurrence rate
- early-onset seizures (within 7-14 days of stroke onset, with a peak within 24 hours)
- stroke-related epilepsy (STRE)
- refers to recurrent seizures attributed to a stroke, indicating a chronic condition that requires long-term management (often with antiseizure medications)
- STRE develops in about 1/3 of early-onset and 50% of late-onset seizures (Olsen, 2001)
- stroke-related seizures – isolated or infrequent seizures that occur as a direct result of a stroke and may be early or late-onset
- acute symptomatic seizures (ASS) occur in close temporal association with an acute cerebral insult or disturbance
- the time frame for ASS is typically within 7 (14) days of the event (such as stroke, traumatic brain injury, metabolic disorder, or infection)
- unlike epilepsy, which involves recurrent seizures without a clear immediate cause, ASS are directly related to the transient disturbance caused by the acute condition
Pathophysiology
- early-onset seizures after ischemic strokes are often caused by metabolic disorders
- increase in intracellular Ca2+ and Na+ with a resulting lower threshold for depolarisation, glutamate excitotoxicity, hypoxia, metabolic dysfunction, global hypoperfusion
- seizures after hemorrhagic strokes are thought to be attributable to irritation caused by products of blood metabolism
- late-onset seizures and STRE are associated with persistent changes in neuronal excitability and gliotic scarring that disrupt the normal neuronal network
- these changes can lead to hyperexcitability and epileptogenic foci
- the location and extent of the cerebral insult significantly influence the risk of epilepsy
- hemosiderin deposits after a hemorrhagic stroke are thought to be the cause of an increased irritability
Risk factors
- key risk factors associated with a higher incidence of post‐stroke seizures include
- stroke severity
- multiple / larger lesions
- cortical lesion or hippocampal involvement
- hemorrhagic strokes
- ICH: parenchymal location, presence of malformation
- SAH: MCA aneurysm, concomitant intraparenchymal hematoma
- pre-existing structural brain conditions
- patient age
- early-onset seizures increase the risk of developing epilepsy
Clinical presentation and diagnostic evaluation
Clinical presentation
- seizures typically follow a localization-related semiology
- ~ 2/3 of patients present with focal seizures
- generalized tonic‐clonic seizures are more common in late-onset seizures
- status epilepticus develops in less than 10% of cases
- it may not be always clear whether the patient is having seizures
- post‐stroke seizure, particularly in older people, may present with acute confusion, slowing, behavioral changes, and syncope. These symptoms also frequently lead to a misdiagnosis of stroke recurrence, especially when the patient has postictal paresis (Todd’s paralysis)
- consider atypical presentations of seizure and stroke mimics
Diagnostic evaluation
- diagnosis involves a comprehensive assessment, including:
- patient history
- neurological examination
- electroencephalography (EEG)
- EEG is crucial in differentiating epileptic seizures from other phenomena, such as TIAs or migraine auras
- EEG may be normal in about 5% of cases ⇒ normal EEG does not exclude epileptogenicity
- focal spikes or periodic bilateral discharges are associated with a higher risk of seizures
- neuroimaging
- essential for identifying the epileptogenic zone and assessing the extent of brain damage
- MRI brain is the imaging modality of choice, as it shows a number of abnormalities that may be missed on CT (cortical malformations, hippocampal sclerosis, small mass lesions, and temporal lobe cavernomas)
Management
- antiseizure medications (ASMs) remain the mainstay of epilepsy management in all age groups
- stroke etiology, side effect profiles, and patient comorbidities should be considered when selecting the appropriate drug
- newer AEDs with fewer side effects and drug interactions are preferable, such as levetiracetam (LEV)
- newer AEDs with fewer side effects and drug interactions are preferable, such as levetiracetam (LEV)
- non-pharmacological interventions, such as surgery, may be considered in drug-resistant cases
- the general principles used for managing other types of epilepsy also apply to post-stroke seizures and epilepsy
- inform the driving licence agency
- advice on supervision of activities such as swimming, cooking, etc
- schedule regular follow-ups to monitor for and address any potential drug side effects
Choice of antiseizure medications
- preferred choice in the acute phase: valproic acid (VPA), levetiracetam (LEV), and lacosamide(LCM), as they allow rapid parenteral titration
- phenytoin (PHE) has potential interactions with anticoagulants
- for long-term medication, consider carbamazepine (CBZ), VPA, LEV
- the specific choice will depend on individual factors and potential side effects
Duration of antiseizure medications
- optimal duration of antiseizure medication (ASM) is unknown
- risk of epilepsy is approx. 5-11% (higher in patients with parenchymal hemorrhages and focal neurological deficits)
- most late-onset seizures occur within the first year
- late-onset seizures are more common in patients with early-onset seizures
- duration should be guided by stroke etiology, the presence and extent of parenchymal lesions, EEG findings, and the timing of epileptic seizures (early x late)
- no strict recommendation; an individualized approach is advised to avoid unnecessary long-term ASM use
- isolated symptomatic seizure (<2 weeks after stroke onset) without large parenchymal lesion ⇒ AED therapy can be gradually tapered within 2-4 weeks after the acute phase
- isolated symptomatic seizure or multiple ASS with parenchymal lesion and/or pathological EEG ⇒ continue ASM treatment for up to 12 months
- post-stroke epilepsy (at least two seizures > 2 weeks after stroke onset) ⇒ long-term ASM is reasonable
- isolated symptomatic seizure (<2 weeks after stroke onset) without large parenchymal lesion ⇒ AED therapy can be gradually tapered within 2-4 weeks after the acute phase
Prophylactic use of antiseizure medications
- ischemic stroke: prophylactic use of antiseizure medication (ASM) is not recommended for ischemic stroke (AHA/ASA 2013 III/C)
- CVST: prophylactic treatment in the first 7-14 days after diagnosis of CVST may be considered (based on the ICSVT study results)
- patients with hemiparesis and parenchymal lesions are at higher risk for ASS
- prophylactic treatment does not lower the risk of post-CVST epilepsy
- SAH: prophylactic antiseizure medication is not routinely recommended; prophylactic therapy in the first 7-14 days may be considered in individual cases to prevent aneurysm rupture during a seizure
- ICH: prophylactic antiseizure medication is not routinely recommended
Prevention
- specific prevention of post-stroke epilepsy is not possible
- however, recanalization therapy and treatment and prevention of complications may reduce the extent of permanent brain damage (extent of lesion and stroke severity are significant risk factors for STRE)